Scinogy Leadership Team

Having worked together as specialists in cell therapy manufacture for nearly 15 years, we found ourselves in a unique position to have a profound impact on one of the most exciting fields of medicine.  We had already recognized that the approach being used to develop cell therapies was not scalable, transferable or commercially viable.  What was lacking were appropriate strategies and technologies.  Scinogy's solutions are now setting a new benchmark in cell therapy manufacturing.

David James photo.jpeg

David James - CEO

David is an experienced international Executive who has spent nearly 30 years commercializing innovative technologies.  His broad industry experience and balanced technical and commercial perspective have helped launch several market leading instruments, consumables and manufacturing systems for Cell Therapy and Diagnostics.  David is a regular conference speaker, guest lecturer for the Department of Chemical and Bio-molecular Engineering (University of Melbourne) and author of multiple papers and articles.

SRW1 small.jpg

Stephen Wilson - COO

Stephen is an exceptional Consultant and Program Manager, helping companies commercialize innovative technologies across a broad range of industries for nearly 30 years.  His many significant achievements include:

  • Cost of Goods reduction, scale-up strategies and subsequent development of consumables and manufacturing equipment for Cell Therapy and Point of Care
  • Development of functionally closed, high throughput counter-flow centrifuges
  • Development of a family of Transverse Flow Filtration instruments
  • Custom automated equipment for high volume manufacture of several innovative products.
Ian Fitzpatrick.jpg

Ian Fitzpatrick - CTO

Ian is a passionate and innovative engineer who has been providing Consulting and Program Management services to global Clients commercializing technologies across a broad range of industries for nearly 40 years.  Ian has an impressive track record of creating game changing technologies and solutions including:

  • Development of closed, automated manufacturing systems for Cell Therapy scale-up
  • Automated manufacturing equipment for several high volume products
  • Diagnostic instruments and consumables development and manufacturing scale-up
  • Cost of Goods reduction strategy for high volume pharmaceutical delivery devices coming "off-patent".